Carmed Pharmaceuticals, a company specializing in standardized carvacrol-based formulations, is drawing attention to the publication of a new peer-reviewed scientific study involving two of its flagship products, Vacrol® and S-Mix®. The research, published in the journal Antioxidants, marks the second peer-reviewed publication in 2026 featuring Carmed formulations, underscoring the company's dedication to scientific investigation and academic collaboration.
The study evaluated Vacrol® and S-Mix® through laboratory and preclinical models, examining formulation characteristics, biological activity, and antimicrobial properties. Researchers concluded that the formulations exhibited distinct biological profiles and recommended further mechanistic and translational research. This latest paper follows a January 2026 study in Plants that also assessed Carmed formulations, contributing to a growing body of literature on standardized carvacrol-based products.
According to the company, this focus on research distinguishes it from many wellness companies that prioritize marketing over science. "Scientific inquiry has always been central to our philosophy," said Mustafa Can, Founder of Carmed Pharmaceuticals. "We believe meaningful innovation requires ongoing research, independent evaluation, and a willingness to explore important scientific questions through rigorous study." Carmed emphasizes that the published research is not intended to claim that its products diagnose, treat, cure, or prevent any disease, but rather reflects scientific exploration into formulation science and biological mechanisms.
Carmed's development approach centers on standardized botanical formulations designed for reproducibility, analytical validation, and quality control. The company collaborates with researchers, laboratories, healthcare institutions, and scientific advisors to support ongoing investigation into botanical bioactives and potential mechanisms of action. "Research is not a marketing exercise for us," said Ceren Can, Global Brand Director. "We view scientific publication as an important part of transparency and long-term credibility. Our goal is to continue contributing to the scientific conversation while making our formulations more accessible to consumers."
The announcement comes as Carmed expands its presence in the United States. Several formulations, including Vacrol® Kids Spray, S-Mix®, Vacrol® Capsule, and Vacrol-M® Capsule, are now available to U.S. consumers through OneLavi.com, with plans to launch on Amazon soon. These products are designed to support immune function, respiratory wellness, and microbial balance. The company states that expanding retail availability alongside continued scientific publication reflects its broader strategy of combining research, quality-focused development, and long-term brand building in the U.S. market.
For more information, visit the Carmed Pharmaceuticals website.
